CoChat

Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis

Open access

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Abstract

Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src kinase. This phosphorylation inhibits the binding of effector Raf while promoting the engagement of GTPase-activating protein (GAP) and GTP hydrolysis. Here we identify SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and dephosphorylates Ras to increase its association with Raf and activate downstream proliferative Ras/ERK/MAPK signalling. In comparison to normal astrocytes, SHP2 activity is elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V) knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting hyperactive Ras. Pharmacologic inhibition of SHP2 activity attenuates cell proliferation, soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model. These results identify SHP2 as a direct activator of Ras and a potential therapeutic target for cancers driven by a previously ‘undruggable’ oncogenic or hyperactive Ras.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms9859

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Tyrosine phosphatase SHP2 dephosphorylates wild-type and oncogenic Ras. (a) HEK293 cells transfected with the indicated plasmids were treated with the indicated inhibitors, lysed, immunoprecipitated with anti-HA antibody and immunoblotted with the indicated antibodies. (b) HEK293 cells transfected with the indicated plasmids were treated with increasing concentrations of II-B08, lysed, immunoprecipitated with anti-HA antibody and immunoblotted with the indicated antibodies. (c) HEK293 cells transfected with the indicated combination of plasmids and monobodies were lysed, immunoprecipitated with anti-HA antibody and immunoblotted with the indicated antibodies. (d,e) HEK293 cells transfected with the indicated plasmids were lysed, immunoprecipitated with anti-HA antibody and immunoblotted with the indicated antibodies. (f) Bacterially purified recombinant human GST-H-Ras(WT) was subjected to in vitro kinase assay in the presence of bacterially purified recombinant human active Src kinase. Subsequent dephosphorylation reaction was conducted using increasing amounts of bacterially purified recombinant human active GST-SHP2 followed by immunoprecipitation (IP) with anti-Ras antibody and immunoblotted with the indicated antibodies. The immunoblot data are representative of at least three separate experiments. WCE, whole-cell extract.
Figure 1 Tyrosine phosphatase SHP2 dephosphorylates wild-type and oncogenic Ras. (a) HEK293 cells transfected with the indicated plasmids were treated with the indicated inhibitors, lysed, immunoprecipitated with anti-HA antibody and immunoblotted with the indicated antibodies. (b) HEK293 cells transfected with the indicated plasmids were treated with increasing concentrations of II-B08, lysed, immunoprecipitated with anti-HA antibody and immunoblotted with the indicated antibodies. (c) HEK293 cells transfected with the indicated combination of plasmids and monobodies were lysed, immunoprecipitated with anti-HA antibody and immunoblotted with the indicated antibodies. (d,e) HEK293 cells transfected with the indicated plasmids were lysed, immunoprecipitated with anti-HA antibody and immunoblotted with the indicated antibodies. (f) Bacterially purified recombinant human GST-H-Ras(WT) was subjected to in vitro kinase assay in the presence of bacterially purified recombinant human active Src kinase. Subsequent dephosphorylation reaction was conducted using increasing amounts of bacterially purified recombinant human active GST-SHP2 followed by immunoprecipitation (IP) with anti-Ras antibody and immunoblotted with the indicated antibodies. The immunoblot data are representative of at least three separate experiments. WCE, whole-cell extract.CC BY · PubMed Central
Figure 2 SHP2 and Ras activities are elevated in mouse and human GBM cell lines and primary patient-derived GBM specimen. (a) RasB8p0 or p3 astrocytes expressing the HA-H-Ras(12V) transgene derived from GBM-prone mice were either lysed and immunoblotted with the indicated antibodies (top panel) or subjected to SHP2 activity assay (bottom panel). Data represent mean±s.e.m. of three independent experiments performed in triplicate. *P<0.05 Student's t-test compared with RasB8p0. (b) RasB8p3 astrocytes were serum starved and pretreated with (+) or without (−) II-B08 followed by treatment with (+) or without (−) 1 ng ml−1 of EGF. Equal amounts of lysates were immunoprecipitated with anti-HA antibody and immunoblotted with the indicated antibodies. (c) Normal human astrocytes (NHA), U87 human GBM astrocytes or U87 astrocytes stably expressing EGFRviii deletion mutant (U87-viii) were either lysed and immunoblotted with the indicated antibodies (top panel) or subjected to SHP2 activity assay (bottom panel). Data represent mean±s.e.m. of three independent experiments performed in triplicate. *P<0.05 Student's t-test compared with NHA. (d) U87 astrocytes were treated with (+) or without (−) lambda phosphatase (λ PPase), II-B08 or sodium orthovanadate (Na3V04) were lysed, immunoprecipitated with anti-Ras antibody and immunoblotted with indicated antibodies. (e) U87 astrocytes were serum starved and pretreated with (+) or without (−) PP2 or II-B08 and treated with (+) or without (−) 1 ng ml−1 of EGF, lysed, immunoprecipitated with anti-Ras antibody and immunoblotted with the indicated antibodies. (f) Patient-derived GBM or grade II astrocytoma samples were lysed pulled down using Raf:RBD beads, and immunoblotted with indicated antibodies. The immunoblot data are representative of at least three separate experiments. IP, immunoprecipitation; WCE, whole-cell extract.
Figure 2 SHP2 and Ras activities are elevated in mouse and human GBM cell lines and primary patient-derived GBM specimen. (a) RasB8p0 or p3 astrocytes expressing the HA-H-Ras(12V) transgene derived from GBM-prone mice were either lysed and immunoblotted with the indicated antibodies (top panel) or subjected to SHP2 activity assay (bottom panel). Data represent mean±s.e.m. of three independent experiments performed in triplicate. *P<0.05 Student's t-test compared with RasB8p0. (b) RasB8p3 astrocytes were serum starved and pretreated with (+) or without (−) II-B08 followed by treatment with (+) or without (−) 1 ng ml−1 of EGF. Equal amounts of lysates were immunoprecipitated with anti-HA antibody and immunoblotted with the indicated antibodies. (c) Normal human astrocytes (NHA), U87 human GBM astrocytes or U87 astrocytes stably expressing EGFRviii deletion mutant (U87-viii) were either lysed and immunoblotted with the indicated antibodies (top panel) or subjected to SHP2 activity assay (bottom panel). Data represent mean±s.e.m. of three independent experiments performed in triplicate. *P<0.05 Student's t-test compared with NHA. (d) U87 astrocytes were treated with (+) or without (−) lambda phosphatase (λ PPase), II-B08 or sodium orthovanadate (Na3V04) were lysed, immunoprecipitated with anti-Ras antibody and immunoblotted with indicated antibodies. (e) U87 astrocytes were serum starved and pretreated with (+) or without (−) PP2 or II-B08 and treated with (+) or without (−) 1 ng ml−1 of EGF, lysed, immunoprecipitated with anti-Ras antibody and immunoblotted with the indicated antibodies. (f) Patient-derived GBM or grade II astrocytoma samples were lysed pulled down using Raf:RBD beads, and immunoblotted with indicated antibodies. The immunoblot data are representative of at least three separate experiments. IP, immunoprecipitation; WCE, whole-cell extract.CC BY · PubMed Central
Figure 3 SHP2 binds to tyrosyl phosphorylated Ras in the presence of Src. (a) HEK293 cells transfected with the indicated plasmids were lysed, immunoprecipitated with anti-Flag antibody and immunoblotted with the indicated antibodies. (b) Wild-type MEFs or Src/Yes/Fyn triple-knockout (SYF−/−) MEFs were serum starved and pretreated with (+) or without (−) II-B08 and then treated with (+) or without (−) 1 ng ml−1 of EGF. Equal amounts of lysates were immunoprecipitated with anti-SHP2 antibody and immunoblotted with the indicated antibodies. (c) U87 astrocytes were serum starved and pretreated with (+) or without (−) II-B08 followed by a treatment with (+) or without (−) 1 ng ml−1 of EGF, lysed, immunoprecipitated with anti-Ras antibody and immunoblotted with indicated antibodies. (d) RasB8p3 astrocytes expressing the HA-H-Ras(12V) transgene were serum starved and pretreated with (+) or without (−) indicated concentration of II-B08 followed by treatment with (+) or without (−) 1 ng ml−1 of EGF, lysed, immunoprecipitated with control rabbit IgG or anti-HA antibody and immunoblotted with the indicated antibodies. The immunoblot data are representative of at least three separate experiments. IP, immunoprecipitation; WCE, whole-cell extract.
Figure 3 SHP2 binds to tyrosyl phosphorylated Ras in the presence of Src. (a) HEK293 cells transfected with the indicated plasmids were lysed, immunoprecipitated with anti-Flag antibody and immunoblotted with the indicated antibodies. (b) Wild-type MEFs or Src/Yes/Fyn triple-knockout (SYF−/−) MEFs were serum starved and pretreated with (+) or without (−) II-B08 and then treated with (+) or without (−) 1 ng ml−1 of EGF. Equal amounts of lysates were immunoprecipitated with anti-SHP2 antibody and immunoblotted with the indicated antibodies. (c) U87 astrocytes were serum starved and pretreated with (+) or without (−) II-B08 followed by a treatment with (+) or without (−) 1 ng ml−1 of EGF, lysed, immunoprecipitated with anti-Ras antibody and immunoblotted with indicated antibodies. (d) RasB8p3 astrocytes expressing the HA-H-Ras(12V) transgene were serum starved and pretreated with (+) or without (−) indicated concentration of II-B08 followed by treatment with (+) or without (−) 1 ng ml−1 of EGF, lysed, immunoprecipitated with control rabbit IgG or anti-HA antibody and immunoblotted with the indicated antibodies. The immunoblot data are representative of at least three separate experiments. IP, immunoprecipitation; WCE, whole-cell extract.CC BY · PubMed Central
Figure 4 SHP2 inhibition promotes tyrosyl phosphorylation of wild-type and oncogenic Ras leading to inactivation of Ras and downstream signalling. (a) HEK293 cells transfected with the indicated plasmids were lysed, immunoprecipitated with anti-HA antibody or were pulled down using Raf:RBD beads or GTP beads, and immunoblotted with the indicated antibodies. (b) HEK293 cells transfected with the indicated plasmids were lysed, immunoprecipitated with anti-Ras antibody and immunoblotted with the indicated antibodies. (c) HEK293 cells transfected with the indicated plasmids were lysed, pulled down using Raf:RBD and immunoblotted with the indicated antibodies. (d) HEK293 cells transfected with the indicated plasmids were lysed, immunoprecipitated with anti-HA antibody or were pulled down using Raf:RBD beads or GTP beads, and immunoblotted with the indicated antibodies. (e) RasB8p3 astrocytes expressing the HA-H-Ras(12V) transgene were serum starved and pretreated with (+) or without (−) II-B08 followed by treatment with (+) or without (−) 1 ng ml−1 of EGF, lysed, pulled down using Raf:RBD beads and immunoblotted with indicated antibodies. (f) Equal number of RasB8p3 astrocytes were plated in 96-well plates in sextuplicate and treated with or without (dimethylsulphoxide (DMSO)) increasing concentration of II-B08 for 18 h and alamar blue assay was conducted according to the manufacturer's instructions. Data represent mean±s.e.m. of three independent experiments performed in sextuplicates. *P<0.05 Student's t-test compared with DMSO control. (g) Equal number of RasB8 astrocytes were suspended in agar matrix, and treated with or without increasing concentrations of II-B08. Following 10 days incubation, the anchorage-independent growth assay was performed according to the manufacturer's instructions. Data represent mean±s.e.m. of three independent experiments performed in sextuplicates. *P<0.05 Student's t-test compared with DMSO control. Representative images are also shown on the left panel captured using a Nikon Coolpix 995 digital camera mounted on a VWR Vista Vision inverted microscope. Scale bar, 200 μm. The immunoblot data are representative of at least three separate experiments. IP, immunoprecipitation; PD, pull down; WCE, whole-cell extract.
Figure 4 SHP2 inhibition promotes tyrosyl phosphorylation of wild-type and oncogenic Ras leading to inactivation of Ras and downstream signalling. (a) HEK293 cells transfected with the indicated plasmids were lysed, immunoprecipitated with anti-HA antibody or were pulled down using Raf:RBD beads or GTP beads, and immunoblotted with the indicated antibodies. (b) HEK293 cells transfected with the indicated plasmids were lysed, immunoprecipitated with anti-Ras antibody and immunoblotted with the indicated antibodies. (c) HEK293 cells transfected with the indicated plasmids were lysed, pulled down using Raf:RBD and immunoblotted with the indicated antibodies. (d) HEK293 cells transfected with the indicated plasmids were lysed, immunoprecipitated with anti-HA antibody or were pulled down using Raf:RBD beads or GTP beads, and immunoblotted with the indicated antibodies. (e) RasB8p3 astrocytes expressing the HA-H-Ras(12V) transgene were serum starved and pretreated with (+) or without (−) II-B08 followed by treatment with (+) or without (−) 1 ng ml−1 of EGF, lysed, pulled down using Raf:RBD beads and immunoblotted with indicated antibodies. (f) Equal number of RasB8p3 astrocytes were plated in 96-well plates in sextuplicate and treated with or without (dimethylsulphoxide (DMSO)) increasing concentration of II-B08 for 18 h and alamar blue assay was conducted according to the manufacturer's instructions. Data represent mean±s.e.m. of three independent experiments performed in sextuplicates. *P<0.05 Student's t-test compared with DMSO control. (g) Equal number of RasB8 astrocytes were suspended in agar matrix, and treated with or without increasing concentrations of II-B08. Following 10 days incubation, the anchorage-independent growth assay was performed according to the manufacturer's instructions. Data represent mean±s.e.m. of three independent experiments performed in sextuplicates. *P<0.05 Student's t-test compared with DMSO control. Representative images are also shown on the left panel captured using a Nikon Coolpix 995 digital camera mounted on a VWR Vista Vision inverted microscope. Scale bar, 200 μm. The immunoblot data are representative of at least three separate experiments. IP, immunoprecipitation; PD, pull down; WCE, whole-cell extract.CC BY · PubMed Central
Figure 5 U87 xenograft mice treated with II-B08 demonstrate reduced tumour burden. (a) U87 astrocytes were serum starved and pretreated with (+) or without (−) increasing concentrations of II-B08 followed by treatment with (+) or without (−) EGF lysed and a pull down (PD) assay was conducted using Raf:RBD beads. (b) U87 astrocytes transfected with the indicated plasmids were treated with or without (dimethylsulphoxide (DMSO)) increasing concentration of II-B08 for 18 h, lysed and immunoblotted with the indicated antibodies. Equal number of U87 astrocytes transfected with indicated plasmids were plated in 96-well plates in sextuplicate, treated with or without (DMSO) increasing concentration of II-B08 for 18 h, and alamar blue (c) or 5-bromodeoxyuridine (BrdU; d) assay was then performed. Data represent mean±s.e.m. of three independent experiments performed in sextuplicates. *P<0.05 Student's t-test compared with DMSO control. (e) Equal number of U87 or U87 astrocytes stably expressing EGFRviii deletion mutant (U87-viii) were plated in 96-well plates in sextuplicate, treated with or without (DMSO) increasing concentration of II-B08 for 18 h, alamar blue assay was performed. Data represent mean±s.e.m. of three independent experiments performed in sextuplicates. *P<0.05 Student's t-test compared with DMSO control. (f) Equal number of U87 or U87-viii astrocytes were suspended in agar matrix and treated with or without increasing concentrations of II-B08. Following 10 days incubation, the anchorage-independent growth assay was performed. Data represent mean±s.e.m. of three independent experiments performed in sextuplicates. *P<0.05 Student's t-test compared with DMSO control. Representative images are shown on top panel captured using a Nikon Coolpix 995 digital camera mounted on a VWR Vista Vision inverted microscope. Scale bar, 200 μm. (g) T2 weighted anatomy MRI imaging demonstrated reduced tumour appearance after 7 days of therapy, which when quantified demonstrates a very significant decrease in the tumour volumetrics when compared with placebo (DMSO)-treated control mice following delayed therapy, beginning at 14 days post injection (**P = 0.0053, Student's t-test) and immediate therapy, beginning at the day of injection (**P = 0.0059, Student's t-test). Eight- to ten-week-old mice were used with n = 11 for delayed treatment group, n = 7 for delayed control group, n = 9 for immediate treatment group and n = 7 for immediate control group. Scale bar, 2 mm. (h) Right hemisphere containing the tumour was lysed from mouse treated with or without II-B08 and immunoprecipitated with anti-Ras or control IgG antibody and immunoblotted using the indicated antibodies. (i) Immunohistochemical staining of U87 tumour tissue following immediate and delayed Il-B08 treatments confirms a reduction in SHP2 and Ki67, whereas TdT-mediated dUTP nick end labelling (TUNEL), an apoptotic indicator, remained similar. Images are representative from untreated or immediate or delayed treated mice with II-B08. (j) Quantification of Ki67 as a % of total cells in the field demonstrates a statistically significant reduction following both treatments (***P<0.0001 ANOVA-post-Tukey). (k) Kaplan–Meier survival curve was plotted for control, immediate and delayed Il-B08-treated mice. The immunoblot data are representative of at least three separate experiments. IP, immunoprecipitation; WCE, whole-cell extract.
Figure 5 U87 xenograft mice treated with II-B08 demonstrate reduced tumour burden. (a) U87 astrocytes were serum starved and pretreated with (+) or without (−) increasing concentrations of II-B08 followed by treatment with (+) or without (−) EGF lysed and a pull down (PD) assay was conducted using Raf:RBD beads. (b) U87 astrocytes transfected with the indicated plasmids were treated with or without (dimethylsulphoxide (DMSO)) increasing concentration of II-B08 for 18 h, lysed and immunoblotted with the indicated antibodies. Equal number of U87 astrocytes transfected with indicated plasmids were plated in 96-well plates in sextuplicate, treated with or without (DMSO) increasing concentration of II-B08 for 18 h, and alamar blue (c) or 5-bromodeoxyuridine (BrdU; d) assay was then performed. Data represent mean±s.e.m. of three independent experiments performed in sextuplicates. *P<0.05 Student's t-test compared with DMSO control. (e) Equal number of U87 or U87 astrocytes stably expressing EGFRviii deletion mutant (U87-viii) were plated in 96-well plates in sextuplicate, treated with or without (DMSO) increasing concentration of II-B08 for 18 h, alamar blue assay was performed. Data represent mean±s.e.m. of three independent experiments performed in sextuplicates. *P<0.05 Student's t-test compared with DMSO control. (f) Equal number of U87 or U87-viii astrocytes were suspended in agar matrix and treated with or without increasing concentrations of II-B08. Following 10 days incubation, the anchorage-independent growth assay was performed. Data represent mean±s.e.m. of three independent experiments performed in sextuplicates. *P<0.05 Student's t-test compared with DMSO control. Representative images are shown on top panel captured using a Nikon Coolpix 995 digital camera mounted on a VWR Vista Vision inverted microscope. Scale bar, 200 μm. (g) T2 weighted anatomy MRI imaging demonstrated reduced tumour appearance after 7 days of therapy, which when quantified demonstrates a very significant decrease in the tumour volumetrics when compared with placebo (DMSO)-treated control mice following delayed therapy, beginning at 14 days post injection (**P = 0.0053, Student's t-test) and immediate therapy, beginning at the day of injection (**P = 0.0059, Student's t-test). Eight- to ten-week-old mice were used with n = 11 for delayed treatment group, n = 7 for delayed control group, n = 9 for immediate treatment group and n = 7 for immediate control group. Scale bar, 2 mm. (h) Right hemisphere containing the tumour was lysed from mouse treated with or without II-B08 and immunoprecipitated with anti-Ras or control IgG antibody and immunoblotted using the indicated antibodies. (i) Immunohistochemical staining of U87 tumour tissue following immediate and delayed Il-B08 treatments confirms a reduction in SHP2 and Ki67, whereas TdT-mediated dUTP nick end labelling (TUNEL), an apoptotic indicator, remained similar. Images are representative from untreated or immediate or delayed treated mice with II-B08. (j) Quantification of Ki67 as a % of total cells in the field demonstrates a statistically significant reduction following both treatments (***P<0.0001 ANOVA-post-Tukey). (k) Kaplan–Meier survival curve was plotted for control, immediate and delayed Il-B08-treated mice. The immunoblot data are representative of at least three separate experiments. IP, immunoprecipitation; WCE, whole-cell extract.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Research works printed but not linked: 1

  1. Kirsten, W. H. & Mayer, L. A. Morphologic responses to a murine erythroblastosis virus. J. Natl Cancer Inst. 39, 311–335 (1967).

Cited by

See all 265

Metadata

Authors
Bunda, S., Burrell, K., Heir, P., Zeng, L., Alamsahebpour, A., Kano, Y., Raught, B., Zhang, Z.-Y., Zadeh, G., & Ohh, M.
Affiliations
  • University of Toronto (CA)
  • University Health Network (CA)
  • Princess Margaret Cancer Centre (CA)
  • Indiana University Indianapolis (US)
Corresponding author
Ohh, Michael
Venue
Nature Communications
Published
2015-11-30
Volume
6
Issue
1
Pages
8859-8859
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2254051095
Cited by
249
References
63
Citations by year
2026: 20 · 2025: 21 · 2024: 29 · 2023: 36 · 2022: 30 · 2021: 30 · 2020: 17 · 2019: 20 · 2018: 15 · 2017: 21 · 2016: 10
FWCI
6.65
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
  • PMC
Funders
  • National Institutes of Health
  • Canadian Institutes of Health Research
  • National Cancer Institute (R01CA69202, R01CA069202)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Keywords
SHP2, protein tyrosine phosphatase, Raf activation, glioblastoma, astrocytes, oncogenic Ras, therapeutic target, cell proliferation, tumor growth
MeSH terms
Animals, Cell Line, Female, Glioblastoma, Humans, Male, Mice, Inbred ICR, Phosphorylation, Oncogene Protein p21(ras), Mice, SCID, Mice, Inbred NOD, Mice, Knockout, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.